<DOC>
	<DOCNO>NCT00206622</DOCNO>
	<brief_summary>To determine low effective dose estradiol compare E2/LNG ( 2.2mg/0.69mg ) E2 ( 1.0mg ) dose placebo decrease frequency severity moderate severe hot flush postmenopausal woman</brief_summary>
	<brief_title>Efficacy Safety Study Postmenopausal Women Determine Lowest Effective Dose Relief Moderate Severe Hot-Flushes</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Menopause Reporting minimum 7 moderate severe hot flush per day least 1 week ( 7 consecutive day ) , minimum 50 moderate severe hot flush per week least 1 week ( 7 consecutive day ) Hormonal treatment Contraindication estrogen/progestogen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>